Yonsei University
Seoul, South Korea
NCT Number: NCT01895387
We determined the effects of dietary intervention (replacement of refined rice with whole grains and legumes and a high intake of vegetables) on circulating Lp-PLA2 activity and enzyme activity in peripheral blood mononuclear cells (PBMCs) in patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes.
Looking for future studies?
Notify Me39 year–74 year
All sexes
Interventional
Not applicable
Seoul, South Korea
Ninety-nine patients with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly-diagnosed type 2 diabetes were randomly assigned to either a control group (usual diet with refined rice) or the whole grain group.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
Subjects in the control group maintained their usual diet of refined rice
Time frame: Change from baseline in Lp-PLA2 at 12 weeks
Time frame: Change from baseline in PBMC Lp-PLA2 at 12 weeks
Time frame: Change from baseline in LDL particle size at 12 weeks
Yonsei University
Other
Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05544825
Impaired Fasting Glucose
Yangsan, Gyeungsangnam-do, South Korea
View Trial DetailsNCT04283201
Diabetes Mellitus, Diabetes Mellitus, Type 2
Kyiv, Ukraine
View Trial DetailsNCT03419702
Body Weight, Diabetes Mellitus
Maastricht, Limburg, Netherlands
View Trial DetailsNCT03474562
ASCVD, Cardiovascular Diseases
Seongnam-si, Gyeonggi-do, South Korea
View Trial Details